Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 25 of 272 entries
View as:

Study to Determine the Maximum Tolerated Dose, Safety and Tolerability of a Single Dose of Lanreotide Prolonged Release Formulation (PRF) in Subjects With Acromegaly

Phase: N/A Priority: Normal
NCT ID: NCT02396953 Org: User:
Start: 03/31/15 End: 11/28/17 Due: 11/28/18

Combination of Lanreotide Autogel 120mg and Temozolomide in Progressive GEP-NET

Phase: N/A Priority: Normal
NCT ID: NCT02231762 Org: User:
Start: 10/31/14 End: 06/30/17 Due: 06/30/18

Health Related Quality of Life and Multidimensional Evaluations of Prostate Cancer Subjects Aged ≥ 60 Years Initiating Gonadotropin-Releasing Hormone (GNRH) Agonist Therapy

Phase: N/A Priority: Normal
NCT ID: NCT03516110 Org: User:
Start: 03/09/18 End: 02/28/20 Due: 02/28/21

United Kingdom (UK) Patient Preference Study of Somatuline Autogel and Treatment Administration Setting

Phase: N/A Priority: Normal
NCT ID: NCT04649580 Org: User:
Start: 04/27/21 End: 06/05/22 Due: 06/05/23

A Study of the Combination of Electrical Stimulation and Dysport® in Myofascial Pain Syndrome.

Phase: N/A Priority: Normal
NCT ID: NCT00246142 Org: User:
Start: 04/30/05 End: 06/27/07 Due: 06/27/08

Study to Assess Efficacy and Safety of Lanreotide Autogel 120 MG in Treatment of Clinical Symptoms Associated With Inoperable Malignant Intestinal Obstruction

Phase: N/A Priority: Normal
NCT ID: NCT02275338 Org: User:
Start: 11/19/14 End: 11/09/17 Due: 11/09/18

Quality of Life of Patients With Locally Advanced and Metastatic Prostate Cancer

Phase: N/A Priority: Normal
NCT ID: NCT02853409 Org: User:
Start: 01/31/14 End: 12/31/15 Due: 12/31/16

Define the Optimal Uptake Time of 68Ga-OPS202 When Used as a PET (Positron Emission Tomography) Imaging Agent in Subjects With Newly Diagnosed Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT03697551 Org: User:
Start: 10/22/18 End: 02/06/19 Due: 02/06/20

Longitudinal Study for Treatment With Botulinum Toxin A Injections in naïve and Pre-treated Patients Suffering From Cervical Dystonia [CD-NIS-Longterm]

Phase: N/A Priority: Normal
NCT ID: NCT01840462 Org: User:
Start: 07/31/12 End: 03/31/16 Due: 03/31/17

Efficacy and Safety Study of Pamoate of Triptorelin in Children With Precocious Puberty

Phase: N/A Priority: Normal
NCT ID: NCT00564850 Org: User:
Start: 10/31/07 End: 10/31/10 Due: 10/31/11

Study on the Utilization of Cabozantinib in Adult Patients With Advanced or Metastatic Renal Cell Carcinoma (RCC) in 2nd Line Treatment Following Prior Vascular Endothelial Growth Factor (VEGF)-Targeted Therapy Under Real-real Life Clinical Setting in France.

Phase: N/A Priority: Normal
NCT ID: NCT04609800 Org: User:
Start: 11/06/20 End: 05/10/23 Due: 05/10/24

Study Of Tasquinimod In Asian Chemo-Naïve Patients With Metastatic Castrate-Resistant Prostate Cancer

Phase: N/A Priority: Normal
NCT ID: NCT02057666 Org: User:
Start: 01/31/14 End: 05/31/15 Due: 05/31/16

A Study of EGb 761® (Tanakan®) in Dementia of Alzheimer Type Onset in Patients Suffering From Memory Complaints

Phase: N/A Priority: Normal
NCT ID: NCT00276510 Org: User:
Start: 02/28/02 End: 11/30/09 Due: 11/30/10

Predictive Factors of Response to Somatostatin Analogues in Acromegalic Patients With Persistent Disease Following Surgery

Phase: N/A Priority: Normal
NCT ID: NCT00500227 Org: User:
Start: 09/30/07 End: 07/31/12 Due: 07/31/13

To Evaluate the Optimal Dose of 68Ga-OPS202 as a PET (Positron Emission Tomography) Imaging Agent in Subjects With Gastroenteropancreatic Neuroendocrine Tumour (GEP-NET)

Phase: N/A Priority: Normal
NCT ID: NCT03220217 Org: User:
Start: 09/26/17 End: 08/05/19 Due: 08/05/20

Study to Compare the Oestradiol Suppression, Clinical Efficacy and Safety of Two Formulations of Triptorelin (Triptorelin Pamoate PR 3-month and Triptorelin Acetate PR 1-month) in Chinese Subjects With Endometriosis

Phase: N/A Priority: Normal
NCT ID: NCT03232281 Org: User:
Start: 07/28/17 End: 11/16/19 Due: 11/16/20

Study to Evaluate the Safety and Activity (Including Distribution) of 177Lu-3BP-227 in Subjects With Solid Tumours Expressing Neurotensin Receptor Type 1.

Phase: N/A Priority: Normal
NCT ID: NCT03525392 Org: User:
Start: 05/03/18 End: 04/28/21 Due: 04/28/22

Study Comparing Short Term Efficacy of Dysport and Dysport NG to Placebo, and to Assess Efficacy and Safety of Dysport NG of Subjects With Cervical Dystonia

Phase: N/A Priority: Normal
NCT ID: NCT01261611 Org: User:
Start: 04/30/11 End: 06/30/13 Due: 06/30/14

Validation of the Spasticity Related Quality of Life Questionnaire

Phase: N/A Priority: Normal
NCT ID: NCT03442660 Org: User:
Start: 05/25/18 End: 08/09/19 Due: 08/09/20

Effects of Triptorelin When Given Every 6-months Under the Skin to Adult Males With Cancer in the Prostate

Phase: N/A Priority: Normal
NCT ID: NCT05458856 Org: User:
Start: 08/30/22 End: 07/08/24 Due: 07/08/25

A Study to Compare Onivyde Manufactured at Two Different Production Sites in Adult Participants With Advanced Cancer in the Pancreas

Phase: N/A Priority: Normal
NCT ID: NCT05383352 Org: User:
Start: 05/30/22 End: 04/15/25 Due: 04/15/26

rhGH and rhIGF-1 Combination Therapy in Children With Short Stature Associated With IGF-1 Deficiency

Phase: N/A Priority: Normal
NCT ID: NCT00572156 Org: User:
Start: 12/31/07 End: 03/31/12 Due: 03/31/13

MM-398 (Nanoliposomal Irinotecan, Nal-IRI) to Determine Tumor Drug Levels and to Evaluate the Feasibility of Ferumoxytol Magnetic Resonance Imaging to Measure Tumor Associated Macrophages and to Predict Patient Response to Treatment

Phase: N/A Priority: Normal
NCT ID: NCT01770353 Org: User:
Start: 11/30/12 End: 10/02/18 Due: 10/02/19

Dysport® Adult Lower Limb Spasticity Follow-on Study

Phase: N/A Priority: Normal
NCT ID: NCT01251367 Org: User:
Start: 06/30/11 End: 04/30/15 Due: 04/30/16

Study to Assess the Efficacy of Brachytherapy With or Without Hormone Therapy, Using Triptorelin 22.5mg in Patients With Recurrence of Prostate Cancer

Phase: N/A Priority: Normal
NCT ID: NCT01374087 Org: User:
Start: 11/30/11 End: 12/31/14 Due: 12/31/15